Business
Traumakine Data Presented at MHSR Symposium
Traumakine Data Presented at MHSR Symposium.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n Faron Pharmaceuticals Ltd.\n \n \n \n \n (\"Faron\" or \"Company\")\n \n \n \n \n \n \n \n \n \n Traumakine Data on Multi-Organ Dysfunction and Limb Salvage to be Presented at the Military Health System Research Symposium\n \n \n \n \n \n \n \n \n ·\n \n Data further highlights promise of intravenous interferon beta-1a therapy as potential therapeutic for emergency and trauma patients, especially when given early on\n \n \n \n ·\n \n Primates treated with Traumakine at the time of major inflammation due to ischemia showed lower levels of muscle and liver damage markers indicating total body protection\n \n \n \n ·\n \n F\n \n \n ull restoration of limb function seen with no evidence of muscle atrophy or degeneration\n \n \n \n ·\n \n Results align with previously conducted INFORAAA clinical trial where Traumakine showed systemic protection in the form of survival benefit and kidney protection in a setting of multi-organ failure\n \n \n \n \n \n \n \n \n \n Press release, September 13, 2022, at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST)\n \n \n \n \n \n \n \n \n \n TURKU, FINLAND / BOSTON, MA\n \n - Faron Pharmaceuticals Ltd (\n AIM: FARN, First North: FARON\n ), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that data from the preclinical Salvage, Preservation, and Advanced Resuscitation through Endothelial Stabilization (SPARES) study will be presented at the Military Health System Research Symposium (MHSRS) being held in Orlando, Florida, from September 12 - 15, 2022. The data (Abstract ID: MHSRS-22-06010) will be featured in the \"Multi-Organ Dysfunction in Prolonged Field Care Scenarios\" breakout session today from 10:00 AM - 12:00 PM EDT.\n \n \n \n \n \n The SPARES study was a preclinical study, conducted on non-human primates (a representative model for humans), to understand the potential effects of Traumakine, Faron's investigational intravenous interferon beta-1a therapy, on limb salvage and preventing multiple organ dysfunction in prolonged field care scenarios where blood flow to a significantly wounded limb is closed for rescue and transportation. The study was coordinated in conjunction with investigators from Wake Forest Health...